Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2577776 | 0.93 | KCNH2 (0.38) | KCNH2 | |
| SCHEMBL2575022 | 0.89 | KCNH2 (0.38) | KCNH2IL1B | |
| SCHEMBL14735814 | 0.86 | KCNH2 (0.38) | KCNH2 | |
| SCHEMBL2576562 | 0.86 | KCNH2 (0.38) | KCNH2IL1B | |
| SCHEMBL16524128 | 0.85 | KCNH2 (0.38) | KCNH2 | |
| SCHEMBL2576929 | 0.85 | KCNH2 (0.38) | KCNH2 | |
| SCHEMBL14998329 | 0.85 | KCNH2 (0.40) | KCNH2IL1B | |
| SCHEMBL16524132 | 0.85 | KCNH2 (0.40) | KCNH2IL1B | |
| SCHEMBL16524346 | 0.84 | KCNH2 (0.37) | KCNH2 | |
| SCHEMBL16524172 | 0.84 | KCNH2 (0.37) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563365-B1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS INC (US) | 2016-04-20 | — | — | EP | claimed |
| US-8969346-B2 | Amino-pyridazine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2015-03-03 | — | — | US | claimed |
| US-9604965-B2 | Substituted pyridazines as skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150322018-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | ASHCRAFT LUKE W (US) | 2015-11-12 | — | — | US | disclosed |
| EP-2563365-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | Cytokinetics, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322018-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | SLC7A1, F12, C5 | KCNH2 441/4885IL1B 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.